Comparison · NCT01908205-2c18f6e8
Intranasal Oxytocin vs Placebo: Number of Participant Considered Overall Responders
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intranasal Oxytocin vs Placebo: Number of Participant Considered Overall Responders. Trial comparisons, record NCT01908205-2c18f6e8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01908205-2c18f6e8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.32 | 0.172 | 0.516 | wilson | |
| Risk in group 2 | 0.276 | 0.147 | 0.457 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0441 | -0.19 | 0.279 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.16 | 0.51 | 2.64 | log | |
| Odds ratio, group 1 over group 2 | 1.24 | 0.383 | 3.98 | log | |
| Number needed to treat, for one more participant with the outcome on Intranasal Oxytocin than on Placebo | 22.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intranasal Oxytocin | To examine safety and tolerability of INOXT | 8 | 25 | OG000 |
| Group 2 | Placebo | To examine safety and tolerability of INOXT | 8 | 29 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participant Considered Overall Responders
- Description
This will be measured by the Clinical Global Impressions - Improvement Scale - Global (CGI-I-Global) (1-7) (lower score=positive response). The results will be reported as the number of participants that were classified as an overall responder (achieving a score of 1 or 2 on the scale).
- Time frame
- 12 Weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)
- NCT number
- NCT01908205
- Phases
- PHASE2
- Conditions
- Autism Spectrum Disorder
- Interventions
- Intranasal Oxytocin, Placebo
- Lead sponsor
- Holland Bloorview Kids Rehabilitation Hospital
- Results first posted
- 2020-11-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01908205?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01908205-2c18f6e8